NO942959L - Insulinpreparat - Google Patents

Insulinpreparat

Info

Publication number
NO942959L
NO942959L NO942959A NO942959A NO942959L NO 942959 L NO942959 L NO 942959L NO 942959 A NO942959 A NO 942959A NO 942959 A NO942959 A NO 942959A NO 942959 L NO942959 L NO 942959L
Authority
NO
Norway
Prior art keywords
insulin
formulation
zinc
total
present
Prior art date
Application number
NO942959A
Other languages
English (en)
Norwegian (no)
Other versions
NO942959D0 (no
Inventor
James Arthur Hoffmann
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO942959D0 publication Critical patent/NO942959D0/no
Publication of NO942959L publication Critical patent/NO942959L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO942959A 1993-08-13 1994-08-09 Insulinpreparat NO942959L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/106,106 US5534488A (en) 1993-08-13 1993-08-13 Insulin formulation

Publications (2)

Publication Number Publication Date
NO942959D0 NO942959D0 (no) 1994-08-09
NO942959L true NO942959L (no) 1995-02-14

Family

ID=22309529

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942959A NO942959L (no) 1993-08-13 1994-08-09 Insulinpreparat

Country Status (27)

Country Link
US (1) US5534488A (es)
EP (1) EP0646379B1 (es)
JP (1) JPH07149660A (es)
KR (1) KR950005324A (es)
CN (1) CN1109364A (es)
AT (1) ATE207761T1 (es)
AU (1) AU674975B2 (es)
BR (1) BR9403204A (es)
CA (1) CA2129763A1 (es)
CO (1) CO4230235A1 (es)
CZ (1) CZ193794A3 (es)
DE (1) DE69428860T2 (es)
DK (1) DK0646379T3 (es)
ES (1) ES2164691T3 (es)
HU (1) HUT67853A (es)
IL (1) IL110581A0 (es)
NO (1) NO942959L (es)
NZ (1) NZ264197A (es)
PE (1) PE14495A1 (es)
PH (1) PH30757A (es)
PL (1) PL177002B1 (es)
PT (1) PT646379E (es)
RU (1) RU2135205C1 (es)
TW (1) TW326394B (es)
UA (1) UA27874C2 (es)
YU (1) YU50494A (es)
ZA (1) ZA945939B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578238A (en) * 1992-10-30 1996-11-26 Lord Corporation Magnetorheological materials utilizing surface-modified particles
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
CO4970787A1 (es) * 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
EP1396272A1 (en) * 1997-12-23 2004-03-10 Eli Lilly & Company Insoluble Insulin Compositions for Controlling Blood Glucose
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
EP1196446A1 (en) * 1999-06-29 2002-04-17 Eli Lilly And Company Protamine-free insoluble acylated insulin compositions
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
ATE328605T1 (de) * 2000-03-24 2006-06-15 Genentech Inc Verwendung von insulin zur behandlung von knorpelkrankheiten
JP4303959B2 (ja) * 2000-10-06 2009-07-29 ジ アドバイザー − ディフェンス リサーチ アンド ディベラップメント オーガナイゼイション 磁気感受性流体組成物およびその調製方法
JP4104978B2 (ja) * 2000-11-29 2008-06-18 ジ アドバイザー − ディフェンス リサーチ アンド ディベラップメント オーガナイゼイション 磁気流動学的流体組成物およびその製造方法
ES2331150T3 (es) * 2001-02-09 2009-12-22 Genentech, Inc. Metodos para identificar agonistas indirectos de igf-1.
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
EP2272501B1 (en) 2002-01-09 2013-03-20 Emisphere Technologies, Inc. Polymorphs of sodium 4-((4-chloro-2-hydroxybenzoyl) amino) butanoate
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
WO2005072803A1 (en) * 2004-01-16 2005-08-11 Biodel, Inc. Sublingual drug delivery device
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
EP2106790B1 (en) * 2004-03-12 2012-10-24 Biodel, Inc. Rapid acting drug delivery compositions
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
CN102001962B (zh) 2004-05-06 2013-04-03 爱密斯菲尔科技公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钠的晶体的多晶
CA2566161C (en) * 2004-05-14 2013-10-01 Emisphere Technologies, Inc. Aryl ketone compounds and compositions for delivering active agents
PT1773878E (pt) * 2004-07-19 2015-06-05 Biocon Ltd Conjugados de insulina-oligómero, formulaçôes e usos dos mesmos
WO2006017541A2 (en) * 2004-08-03 2006-02-16 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
JP2008509933A (ja) * 2004-08-13 2008-04-03 エミスフェアー・テクノロジーズ・インク 送達剤のマイクロ粒子またはナノ粒子を含む医薬製剤
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
MX2008013165A (es) * 2006-04-12 2009-01-29 Biodel Inc Formulaciones de combinacion de insulina de accion rapida y accion larga.
ES2579229T3 (es) 2007-03-13 2016-08-08 Jds Therapeutics, Llc Procedimientos y composiciones para la liberación sostenida de cromo
WO2008124522A2 (en) * 2007-04-04 2008-10-16 Biodel, Inc. Amylin formulations
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
ES2664822T3 (es) 2007-10-16 2018-04-23 Biocon Limited Una composición farmacéutica sólida administrable por vía oral y un proceso de la misma
WO2009089181A1 (en) * 2008-01-04 2009-07-16 Blodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
BRPI0920881B1 (pt) 2008-10-17 2021-09-21 Sanofi-Aventis Deutschland Gmbh Composição farmacêutica, seu uso e método de preparação da mesma, kit e dispositivo
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
TWI468171B (zh) 2009-11-13 2015-01-11 Sanofi Aventis Deutschland 含ｇｌｐ－１激動劑及甲硫胺酸之醫藥組成物
DK2554183T3 (en) 2009-11-13 2018-07-23 Sanofi Aventis Deutschland A pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
MX2012009618A (es) * 2010-02-22 2013-02-26 Univ Case Western Reserve Preperaciones de analogo de insulina de larga accion en formas solubles y cristalinas.
PL2611458T3 (pl) 2010-08-30 2017-02-28 Sanofi-Aventis Deutschland Gmbh Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
EP2680861B1 (en) 2011-03-01 2022-05-04 Nutrition 21, LLC Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
JP6970615B2 (ja) 2014-12-12 2021-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリングラルギン／リキシセナチド固定比処方
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
WO2017139337A1 (en) 2016-02-11 2017-08-17 Nutrition 21, Llc Chromium containing compositions for improving health and fitness

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2626228A (en) * 1945-05-17 1953-01-20 Novo Terapeutisk Labor As Method of producing crystalline insulin
US2882202A (en) * 1950-04-05 1959-04-14 Novo Terapeutisk Labor As Insulin crystal preparations and methods of producing them
US2882203A (en) * 1951-06-26 1959-04-14 Novo Terapeutisk Labor As Injectable insulin preparation with protracted effect
US2849370A (en) * 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
US3102077A (en) * 1953-08-19 1963-08-27 Christensen Henry Marinus Preparation of insulin containing 2.75 to 8 percent zinc content
US2819999A (en) * 1953-11-13 1958-01-14 Novo Terapeutisk Labor As Process for crystallization of insulin using freeze dried insulin as seeding material
US2799622A (en) * 1953-11-14 1957-07-16 Novo Terapeutisk Labor As Process of producing insulin crystals of substantially uniform size and compositions thereof
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
DE2933946A1 (de) * 1979-08-22 1981-03-12 Hoechst Ag, 6000 Frankfurt Insulinkristallsuspension und verfahren zu ihrer herstellung.
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
PH23446A (en) * 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus

Also Published As

Publication number Publication date
HU9402287D0 (en) 1994-09-28
UA27874C2 (uk) 2000-10-16
ATE207761T1 (de) 2001-11-15
IL110581A0 (en) 1994-11-11
CA2129763A1 (en) 1995-02-14
NZ264197A (en) 1997-01-29
PH30757A (en) 1997-10-17
CZ193794A3 (en) 1995-03-15
BR9403204A (pt) 1995-04-18
HUT67853A (en) 1995-05-29
PE14495A1 (es) 1995-06-02
DE69428860T2 (de) 2002-05-02
TW326394B (en) 1998-02-11
JPH07149660A (ja) 1995-06-13
PT646379E (pt) 2002-03-28
PL177002B1 (pl) 1999-09-30
CN1109364A (zh) 1995-10-04
EP0646379B1 (en) 2001-10-31
ZA945939B (en) 1996-02-08
RU2135205C1 (ru) 1999-08-27
US5534488A (en) 1996-07-09
DK0646379T3 (da) 2001-12-03
DE69428860D1 (de) 2001-12-06
AU674975B2 (en) 1997-01-16
CO4230235A1 (es) 1995-10-19
AU7024794A (en) 1995-02-23
YU50494A (sh) 1997-01-08
NO942959D0 (no) 1994-08-09
EP0646379A1 (en) 1995-04-05
ES2164691T3 (es) 2002-03-01
PL304600A1 (en) 1995-02-20
KR950005324A (ko) 1995-03-20

Similar Documents

Publication Publication Date Title
DK0646379T3 (da) Insulinformulering
AU610636B2 (en) Stabilised human protein preparations
CY1646A (en) Use of n-(4-phenoxy-2,6-diisopropylphenyl)-n'-tert.butylthiourea in the control of white flies
ES8101382A1 (es) Un procedimiento para la obtencion de un aglutinante para los tejidos a base de proteinas humanas o animales
AU5707294A (en) 3,3 diphenyl prop-2-yl amino acid derivatives and their use as tachykinin antagonists
GB9108652D0 (en) Immunoreactive compounds
CA2015186A1 (en) Nutrient composition
AU2670495A (en) Ifn-beta liquid formulations
AU8188087A (en) Variants of hirudin, their use and their preparation
EP0511903A3 (en) Conjugate of calcitonin and polyethylene glycol
AU624079B2 (en) Novel fluorinated derivatives of amino acids usable more particularly as surfactants or cosurfactants and preparations for biomedical use incorporating these derivatives
AU6406590A (en) Porcine lactoferrin amino acid and cdna sequence
AU8375891A (en) Antioxidant system based on a basic amino acid in combination with a tocopherol or derivative thereof and a nonthiolated polypeptide, and compositions containing the same
MD1714G2 (ro) Compoziţie terapeutică în formă de sirop, conţinând N-acetilcisteină
ATE149354T1 (de) Pharmazeutische zusammensetzung von stabilisiertem (leu 13>-motilin-hse
ATE262307T1 (de) Verwendung von goldlegierungen für konstruktionselemente in der dentaltechnik
CA2153071A1 (en) Derivatized calcitonins
EP0292302A3 (en) Human splenin
CA2247998A1 (en) Fragments of cr1 and their use
HU201445B (en) Herbicide composition containing sulfonyl-urea derivative as active component and glycinamide derivative as antidotum
TH17521EX (th) สูตรผสมอินซูลิน

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application